Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of HRS-9190 injection for neuromuscular blockade during general anesthesia
CTR20262994Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-9190 in None, sponsored by Hengrui Therapeutics. Started Sep 2026; status: active.
02
Drugs
HRS-9190
Beyond the preview
Go deeper on CTR20262994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262994.